Aptose's TUS+VEN+AZA triplet data selected for oral presentation at EHA 2025 Congress

Aptose Biosciences Inc.

Data from TUSCANY Phase 1/2 trial of tuspetinib (TUS) + venetoclax + azacitidine in newly diagnosed AML accepted for oral presentation at EHA 2025 (June 12-15, Milan).
Oral presentation will include updated safety, complete remission, and MRD data at 40 mg and 80 mg dose levels with longer follow-up.
Prior data showed safety and complete remissions across diverse mutations including TP53-mutated and FLT3-wildtype patients.
TUS+VEN+AZA is being developed as mutation-agnostic frontline therapy for AML patients ineligible for induction chemotherapy.
Anticipated enrollment of 18-24 patients in TUSCANY trial by mid-late 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.